Aqara Previews New Devices for 2023
5.1.2023 17:00:00 EET | Business Wire | Press release
Aqara, a leading provider of smart home products, is set to expand its product portfolio in 2023 with the addition of innovative sensors, smart door locks, video doorbells and LED strips. Committed to providing seamless connected home experiences to millions of global users, Aqara continues to enrich its offerings with latest smart home technologies and new device types.
Video Doorbell G4 is complementary to Aqara’s indoor home cameras, and together these cameras help users to keep an eye on their homes, families and visitors anytime, anywhere. This doorbell allows highly flexible installation as it can be battery-powered or wired for continuous power. It not only supports HomeKit Secure Video and local streaming to Amazon and Google smart displays, but it will also work with Matter after the Matter specification for cameras is ready. The G4 features local, AI-enabled facial recognition, which can trigger different automations depending on the person, and the device also includes both the 7-day free cloud storage and the optional local storage via a microSD card.
Presence Sensor FP2 is a revolutionary addition to the Company’s wide-ranged sensor lineup. Based on the millimeter wave (mmWave) radar technology, the FP2 detects human presence even when the person is sitting still. It enables zone positioning, which allows users to define different zones within a room such as the bed, the dresser, or the sofa area, and the presence in each of these individual zone can trigger different automations for a more customized experience. Other features include multi-person detection, fall-detection and a built-in light sensor.
Smart Lock U100 is the first deadbolt lock from Aqara, offering a secure and convenient home access solution that can be seamlessly integrated into modern smart homes. The U100 lock is one of the few smart locks in the market that is compatible with HomeKit and supports the home key feature in Apple Wallet. Other access authentication options include fingerprints, passwords, Aqara Home app, NFC cards, and mechanical keys. Based on the Zigbee protocol, the U100 supports Matter via a compatible Aqara hub.
LED Strip T1 is a multipurpose RGB CCT lightstrip that is intended to enrich smart lighting experiences for Aqara users. It produces up to 16 million vibrant colors and tunable white light, and is addressable with gradient effects. HomeKit, Alexa and Google Home are supported, and Matter support via a compatible Aqara hub is expected to be added after its launch. The LED strip is Zigbee-based which means lower power consumption as well as less congested home Wi-Fi network, and it also serves as a repeater that enhances the Zigbee network.
These devices from Aqara will become available for purchase in the following months. For more information of these products, please check a demonstrative video here.
Committed to enabling seamless user experiences, Aqara has been working to integrate Matter into its existing and new devices. In 2023 new OTA updates will be pushed to Aqara hubs - beginning from the M2 - so that they can serve as Matter bridges and connect Aqara Zigbee devices to Matter. Moreover, the Company also confirmed a new lineup of Thread-based devices with native Matter support this year, including the Door and Window Sensor P2 and the Motion and Light Sensor P2 which are expected to hit the market in the coming months. As part of the ongoing partnerships with Aqara, both Google and Samsung are featuring these new sensors on respective booths at CES 2023, along with other Aqara devices including the Hub M2 as a Matter bridge.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005437/en/
Contact information
For Media Inquiry:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom